Tumor heterogeneity and strategies to overcome kinase inhibitor resistance in cancer: Lessons from melanoma

Expert Opinion on Investigational Drugs

Volumn 20, Issue 2, 2011, Pages 137-140

  Rebecca, Vito W ^a   Smalley, Keiran S M ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; BCR ABL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GSK 1120212; GSK 2118436; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; PLX 4032; SELUMETINIB; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG;

CANCER RESISTANCE; CELL HETEROGENEITY; GENE DOSAGE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; MELANOMA; PHENOTYPE; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; MAP KINASE SIGNALING SYSTEM; MELANOMA; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SIGNAL TRANSDUCTION;

EID: 79951900560     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2011.546218     Document Type: Review

References (19)

1. Barouch-Bentov R, Sauer K. Mechanisms of dug-resistance in kinases. Expert Opin Investig Drugs 2011;20(2):153-208.
2. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363(9):809-19.
3. Smalley KSM, Sondak VK. Melanoma - an unlikely poster child for targeted therapy. N Engl J Med 2010;363:876-78.
4. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation. Nature 2010 Nov 24. [Epub ahead of print].
5. Villanueva J, Vultur A, Lee JT, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010;18(6):683-95.
6. Paraiso KH, Fedorenko IV, Cantini LP, et al. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer 2010;102(12):1724-30.
7. Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA 2009;106(48):20411-16.
8. Jiang CC, Lai F, Thorne RF, et al. MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720. Clin Cancer Res 2010 Nov 18. [Epub ahead of print].
9. Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010 Nov 24. [Epub ahead of print].
10. Corcoran RB, Dias-Santagata D, Bergethon K, et al. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal 2010;3(149):ra84.
11. Stommel JM, Kimmelman AC, Ying H, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007;318(5848):287-90. (Pubitemid 47574858)
12. Sensi M, Nicolini G, Petti C, et al. Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma. Oncogene 2006;25(24):3357-64. (Pubitemid 43877040)
13. Jovanovic B, Egyhazi S, Eskandarpour M, et al. Coexisting NRAS and BRAF mutations in primary familial melanomas with specific CDKN2A germline alterations. J Invest Dermatol 2010;130(2):618-20.
14. Poulikakos PI, Zhang C, Bollag G, et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010;464(7287):427-30.
15. Kaplan FM, Shao Y, Mayberry MM, Aplin AE. Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the ongenic B-RAF inhibitor, PLX4720, in mutant N-Ras melanoma cell lines. Oncogene 2010 Sep 6. [Epub ahead of print].
16. Roesch A, Fukunaga-Kalabis M, Schmidt EC, et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 2010;141(4):583-94.
17. Sharma SV, Lee DY, Li B, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010;141(1):69-80.
18. Smalley KS, Nathanson KL, Flaherty KT. Genetic subgrouping of melanoma reveals new opportunities for targeted therapy. Cancer Res 2009;69(8):3241-4.
19. Smalley KS, Haass NK, Brafford PA, et al. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 2006;5(5):1136-44 (Pubitemid 43881305)